| Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript |
Pharming Group N.V. (NASDAQ:PHAR ) Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ET Company Participants Fabrice Chouraqui – CEO Stephen Toor – CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Joe Pantginis - H.C. |
seekingalpha.com |
2025-05-09 12:50:38 |
Czytaj oryginał (ang.) |
| Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript |
Pharming Group N.V. (NASDAQ:PHAR ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Fabrice Chouraqui - CEO Stephen Toor - CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Ben Jackson – Jefferies Alistair Campbell - RBC Capital Markets Joe Pantginis - H.C. |
seekingalpha.com |
2025-03-13 21:44:30 |
Czytaj oryginał (ang.) |
| Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders |
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. |
globenewswire.com |
2025-03-04 11:15:00 |
Czytaj oryginał (ang.) |
| Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period |
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this press release and in the offer document published on the transaction website ( www.raredisease-offer.com ). Shareholders in the United States should also refer to the section titled “Special notice to shareholders in the United States” at the end of this press release . |
globenewswire.com |
2025-02-07 18:00:00 |
Czytaj oryginał (ang.) |
| European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug |
On Wednesday, Pharming Group N.V. PHAR revealed topline results of data from its Phase 3 trial evaluating leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). |
benzinga.com |
2024-12-11 11:34:42 |
Czytaj oryginał (ang.) |
| Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript |
Pharming Group N.V. (NASDAQ:PHAR ) Q3 2024 Earnings Conference Call October 24, 2024 7:30 AM ET Company Participants Sijmen de Vries - Chief Executive Officer & Executive Director Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Sushila Hernandez - Kempen Joe Pantginis - H.C. |
seekingalpha.com |
2024-10-24 17:44:05 |
Czytaj oryginał (ang.) |
| Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript |
Pharming Group NV (NASDAQ:PHAR ) Q2 2024 Earnings Conference Call August 1, 2024 7:30 AM ET Company Participants Sijmen de Vries - CEO & Executive Director Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Sushila Hernandez - Van Lanschot Kempen Jeff Jones - Oppenheimer Alistair Campbell - RBC Capital Markets Simon Scholes - First Berlin Sijmen de Vries Good morning or good afternoon, ladies and gentlemen; I'm here. Next slide, please. |
seekingalpha.com |
2024-08-02 19:26:07 |
Czytaj oryginał (ang.) |
| Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union |
L eiden , the Netherlands, May 30, 2024 : Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). |
globenewswire.com |
2024-05-30 20:44:00 |
Czytaj oryginał (ang.) |
| Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders |
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item 4.b), upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years. |
globenewswire.com |
2024-05-21 15:30:00 |
Czytaj oryginał (ang.) |
| Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript |
Pharming Group N.V. (NASDAQ:PHAR ) Q1 2024 Earnings Conference Call May 8, 2024 7:30 AM ET Company Participants Sijmen de Vries - Executive Director and Chief Executive Officer Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Christian Glennie - Stifel Sushila Hernandez - Van Lanschot Kempen Joe Pantginis - H.C. |
seekingalpha.com |
2024-05-12 13:19:10 |
Czytaj oryginał (ang.) |
| Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains? |
Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-04-22 10:31:04 |
Czytaj oryginał (ang.) |
| Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 |
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. |
globenewswire.com |
2024-04-19 16:43:00 |
Czytaj oryginał (ang.) |
| Pharming Group to report fourth quarter and full year 2023 financial results on March 14 |
Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 14, 2024.To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. |
globenewswire.com |
2024-02-29 04:00:00 |
Czytaj oryginał (ang.) |
| Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval |
Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on the timetable included in the CHMP Day 180 Second LoOI, and considering the CHMP's decision to reschedule the Ad-Hoc Expert Group (AEG) meeting to the end of November, Pharming now expects the CHMP to issue its opinion on the leniolisib MAA in the first quarter of 2024. |
globenewswire.com |
2023-11-10 10:51:00 |
Czytaj oryginał (ang.) |
| Pharming Group N.V. (PHAR) Q3 2023 Earnings Call Transcript |
Pharming Group N.V. (PHAR) Q3 2023 Earnings Call Transcript |
seekingalpha.com |
2023-10-27 12:35:10 |
Czytaj oryginał (ang.) |
| Pharming Group N.V. (PHGUF) Q3 2023 Earnings Call Transcript |
Pharming Group N.V. (OTCPK:PHGUF) Q3 2023 Earnings Conference Call October 26, 2023 7:30 AM ET Company Participants Sijmen de Vries - Chief Executive Officer Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Christian Glennie - Stifel Alistair Campbell - Royal Bank of Canada Sushila Hernandez - Van Lanschot Kempen Joe Pantginis - H.C. |
seekingalpha.com |
2023-10-27 02:33:09 |
Czytaj oryginał (ang.) |
| Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock? |
Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average. |
zacks.com |
2023-09-22 08:31:03 |
Czytaj oryginał (ang.) |
| Pharming Group: Pipeline Progresses With APDS Phase 3 Initiation |
Pharming Group NV is a biotechnology firm known for its unique approach to addressing rare and genetic diseases. The company's financials show growth in revenue, primarily driven by strong sales of their leading therapy, Ruconest. Pharming's expansion into organ transplantation fields adds a new dimension to their growth prospects, but challenges remain in gaining acceptance and assessing the impact on their income. |
seekingalpha.com |
2023-09-09 16:30:37 |
Czytaj oryginał (ang.) |
| Pharming Group to participate in September investor conferences |
LEIDEN, The Netherlands , Aug. 24, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the U.S. in the month of September: 2023 Wells Fargo Healthcare Conference, Boston, September 6-8 Sijmen de Vries, Chief Executive Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Thursday, September 7 at 16:30 ET/22:30 CET. |
prnewswire.com |
2023-08-24 06:00:00 |
Czytaj oryginał (ang.) |
| Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan |
Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with APDS, a rare primary immunodeficiency LEIDEN, The Netherlands , Aug. 9, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial in Japan evaluating leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adult and pediatric patients 12 years of age and older. |
prnewswire.com |
2023-08-09 05:00:00 |
Czytaj oryginał (ang.) |
| Pharming Group N.V. (PHAR) Q2 2023 Earnings Call Transcript |
Pharming Group N.V. (NASDAQ:PHAR ) Q2 2023 Earnings Conference Call August 3, 2023 7:30 AM ET Company Participants Sijmen de Vries - Executive Director and Chief Executive Officer Anurag Relan - Chief Medical Officer Stephen Toor - Chief Commercial Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Christian Glennie - Stifel Joseph Pantginis - H.C. |
seekingalpha.com |
2023-08-06 08:51:08 |
Czytaj oryginał (ang.) |
| Pharming Group N.V. (PHGUF) Q2 2023 Earnings Call Transcript |
Pharming Group N.V. (OTCPK:PHGUF) Q2 2023 Earnings Conference Call August 3, 2023 7:30 AM ET Company Participants Sijmen de Vries - CEO Anurag Relan - CMO Stephen Toor - CCO Jeroen Wakkerman - CFO Conference Call Participants Christian Glennie - Stifel Joe Pantginis - H.C. |
seekingalpha.com |
2023-08-06 06:54:01 |
Czytaj oryginał (ang.) |
| Pharming Group to report second quarter and first half 2023 financial results on August 3 |
LEIDEN, The Netherlands , July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023. |
prnewswire.com |
2023-07-13 06:00:00 |
Czytaj oryginał (ang.) |
| Tony's or Wonka? Choc maker issues three ‘golden shares' |
Tony's Chocolonely, the chocolate maker, has issued three ‘golden shares' aimed at maintaining the group's sustainability pledge. The new governing structure is in place in case new shareholders or leadership try to steer the company away from its aim of ending inequality and exploitation in the chocolate industry. |
proactiveinvestors.co.uk |
2023-05-31 15:13:53 |
Czytaj oryginał (ang.) |